Archives: 2022-11-14

PIER MARIA FORNASARI
2022-11-14

Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2

Therapy up to 4.5 years led to gains in motor function: analysis published in Brain & Development Up to 4.5 years of Spinraza (nusinersen) treatment led to meaningful improvements in motor function in adolescents and adults with spinal muscular atrophy (SMA), according to a medical records analysis. “[Spinraza] was effective in long-term follow-up,” researchers wrote. Noting a dearth of

Read More

No Comments InRARE DISEASES
PIER MARIA FORNASARI
2022-11-14

Technion researchers have developed a technology to measure the long-term effect of antibiotic “combination therapies”

Researchers at the Technion have developed a technology to measure the long-term effect of antibiotic combinations (cocktails). These combinations are of concern to the scientific and medical community due to the fact that the use of single antibiotics often leads to the rapid development of bacterial resistance to antibiotics. The research published in Nature was led by Technion

Read More

No Comments InRESEARCH WELLNESS
PIER MARIA FORNASARI
2022-11-14

How Covid-19 leads to neuronal damage

Although the Sars-CoV-2 coronavirus does not affect nerve cells, Covid-19 disease can cause damage to the nervous system. Researchers from the University of Basel and the University Hospital Basel have elucidated the mechanisms behind “Neuro-Covid” and identified starting points for preventing it. Quite a few have lost their sense of smell and taste with the coronavirus

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-11-12

Acute and postacute sequelae associated with SARS-CoV-2 reinfection: increased risk of fatal complications.

Many people worldwide are experiencing repeat SARS-CoV-2 infections, but the health risks associated with these reinfections have remained unclear. Now,  a team of researchers led by Washington University in St. Louis has found that repeated COVID-19 infections increase the risk of organ failure and death. “During the past few months, there’s been an air of invincibility among people who

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-11-12

WHO releases first data on global vaccine market since COVID-19

WHO’s Global Vaccine Market Report 2022, published today, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently struggling to access vaccines that are in-demand by wealthier countries. WHO’s Global Vaccine Market Report 2022, published today, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently struggling to access

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-11-12

Study lead by UMass Chan clinical scientists provides evidence of protective link between oral microbiome and COVID

Oral microbiome composition indicative of need for respiratory support among COVID-19 patients Using high-throughput genome sequencing and machine learning, scientists at UMass Chan Medical School have shown a strong correlation between the oral microbiome in patients with COVID-19 at the time of hospital admission and the need for later respiratory support. Published in Frontiers in Microbiology,

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-11-10

New Exa-cel gene therapy for Sickle Cell Disease and Beta Thalassemia global regulatory submission in 2022

A potential 1-time gene editing treatment for severe sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) is entering approval review by the US Food and Drug Administration (FDA), the European Medicines Agency, and the UK Medicines and Healthcare products Regulatory Agency, according to a company statement. Both diseases involve variants in the gene encoding β globin. The variants

Read More

No Comments InCRISPR GENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-11-09

US FDA grants Rare Pediatric Disease Designation to gene therapy OTOF-GT for the treatment of otoferlin gene-mediated hearing loss

OTOF-GT targets the restoration of hearing in people living with otoferlin deficiency Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-11-09

Which COVID Vaccine You Get Can Impact Myocarditis Risk: study published in the Journal of the American College of Cardiology

Study shows higher rates of heart inflammation with Moderna vs. Pfizer, but overall risk still very low Incidence of myocarditis, pericarditis or myopericarditis is two- to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine when compared to the Pfizer BioNTech COVID-19 vaccine; however, overall cases of heart inflammation with either vaccine

Read More

No Comments InCovid-19